STVN N Stock Overview
Engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Stevanato Group S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$468.64 |
| 52 Week High | US$609.55 |
| 52 Week Low | US$468.64 |
| Beta | 0.58 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 25.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| STVN N | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how STVN N performed against the MX Life Sciences industry.
Return vs Market: Insufficient data to determine how STVN N performed against the MX Market.
Price Volatility
| STVN N volatility | |
|---|---|
| STVN N Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: STVN N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine STVN N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,635 | Franco Stevanato | www.stevanatogroup.com |
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines.
Stevanato Group S.p.A. Fundamentals Summary
| STVN N fundamental statistics | |
|---|---|
| Market cap | Mex$105.45b |
| Earnings (TTM) | Mex$2.68b |
| Revenue (TTM) | Mex$21.31b |
39.4x
P/E Ratio4.9x
P/S RatioIs STVN N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STVN N income statement (TTM) | |
|---|---|
| Revenue | €1.08b |
| Cost of Revenue | €757.43m |
| Gross Profit | €325.93m |
| Other Expenses | €189.75m |
| Earnings | €136.18m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 30.09% |
| Net Profit Margin | 12.57% |
| Debt/Equity Ratio | 26.9% |
How did STVN N perform over the long term?
See historical performance and comparison